Trending...
- New book, "High-Tech Heroes," redefines billionaire as someone who improves a billion lives
- Mensa Foundation Prize Awarded to Neuroscientist-Pianist
- Anti-war groups protest vs US-NATO actions in Gaza, Iran, the Global South
The research study of this unique jellyfish collagen-based supplement was published in the peer-reviewed medical source, the Journal of Clinical Research and Reports.
TEMECULA, Calif. - AussieJournal -- Jellyfish Publication-Certified Nutraceuticals, Inc.
Gerald M. Haase, M.D.
Clinical Professor of Surgery, University of Colorado School of Medicine, Aurora, CO.
Neil E. Wolkodoff, PhD
Medical Program Director, Colorado Center for Health and Sports Science, Denver, CO.
May 16, 2025
Certified Nutraceuticals, Inc., a research and product development enterprise in Pauma Valley, California, U.S.A., announces the publication of an exciting new human clinical trial of its proprietary KollaJell™ collagen peptide formulation.
The research study of this unique jellyfish collagen-based supplement was published in the peer-reviewed medical source, the Journal of Clinical Research and Reports. The strength of this prospective, randomized trial is the distinctive utilization of a panel of brain function metrics from two robust, validated instruments, including a computerized neurocognitive test battery and an electroencephalographic (EEG) profile of voltage activation and wave phase pattern. Instead of evaluating only one or two parameters, this investigation assessed seven domains of cognitive function in 23 subjects who consumed KollaJell™ for a period of eight weeks.
More on Aussie Journal
The outcomes were clinically relevant, and all were statistically analyzed and achieved statistical significance. Standard scores matched for age and gender improved in all metrics regardless of the functional status of where the subject started. The parameters included compositive memory, neurocognitive index, visual memory, executive function and verbal memory. Under EEG monitoring conditions, the mean total reaction time and the trail-making composite test times also decreased dramatically. Topographic brain images showed voltage activation in the brain regions associated with sensory input and processing function. There were no adverse effects of consuming the supplement in any subject at any time during the study.
The importance of this pilot trial is the demonstration of a particularly extensive spectrum of beneficial results from the proprietary formulation compared to competing products that, even if helpful, provide only limited effects. In addition, the use of a marine-based natural collagen was superior to the usual animal-based products and the patented extraction process provided a greater platform of collagen types and a uniquely effective amino acid composition. This human clinical trial reinforces the concept that Certified Nutraceuticals KollaJell™ is a safe and beneficial collagen supplement that supports cognitive domains and memory and is applicable to a wide audience of potential consumers, regardless of their initial brain function status.
More on Aussie Journal
The actual medical study is available as a free open-access publication at https://www.auctoresonline.org/article/effects-of-a-jellyfish-collagen-based-amino-acid-supplement-on-cognitive-function-and-memory-a-pilot-investigation
For further information about the product or study, please contact:
Sara Alkayali at (951) 600-3899 or email: salkayali@certifiednutra.com
Gerald M. Haase, M.D.
Clinical Professor of Surgery, University of Colorado School of Medicine, Aurora, CO.
Neil E. Wolkodoff, PhD
Medical Program Director, Colorado Center for Health and Sports Science, Denver, CO.
May 16, 2025
Certified Nutraceuticals, Inc., a research and product development enterprise in Pauma Valley, California, U.S.A., announces the publication of an exciting new human clinical trial of its proprietary KollaJell™ collagen peptide formulation.
The research study of this unique jellyfish collagen-based supplement was published in the peer-reviewed medical source, the Journal of Clinical Research and Reports. The strength of this prospective, randomized trial is the distinctive utilization of a panel of brain function metrics from two robust, validated instruments, including a computerized neurocognitive test battery and an electroencephalographic (EEG) profile of voltage activation and wave phase pattern. Instead of evaluating only one or two parameters, this investigation assessed seven domains of cognitive function in 23 subjects who consumed KollaJell™ for a period of eight weeks.
More on Aussie Journal
- Shop American Made Goods: New Online Marketplace My American Goods Curates the Best of U.S. Made
- Investor Spotlight: Cycurion, Inc. (N A S D A Q: CYCU) Secures $69M in Contracts Amid Surging Demand for AI-Powered Cybersecurity Solutions
- $328 Million Global Stroke Rehab Market Opportunity Awaits AI Telehealth Leader Following Selection for NIH Funded Phase 3 Clinical Study: VSee Health
- Ascent Solar Technologies Enters Collaborative Agreement Notice with NASA to Advance Development of Thin-Film PV Power Beaming Capabilities: ASTI
- VoodooSoft Unveils SiriusLLM: The World's First ChatGPT-Like AI Malware Detection Engine
The outcomes were clinically relevant, and all were statistically analyzed and achieved statistical significance. Standard scores matched for age and gender improved in all metrics regardless of the functional status of where the subject started. The parameters included compositive memory, neurocognitive index, visual memory, executive function and verbal memory. Under EEG monitoring conditions, the mean total reaction time and the trail-making composite test times also decreased dramatically. Topographic brain images showed voltage activation in the brain regions associated with sensory input and processing function. There were no adverse effects of consuming the supplement in any subject at any time during the study.
The importance of this pilot trial is the demonstration of a particularly extensive spectrum of beneficial results from the proprietary formulation compared to competing products that, even if helpful, provide only limited effects. In addition, the use of a marine-based natural collagen was superior to the usual animal-based products and the patented extraction process provided a greater platform of collagen types and a uniquely effective amino acid composition. This human clinical trial reinforces the concept that Certified Nutraceuticals KollaJell™ is a safe and beneficial collagen supplement that supports cognitive domains and memory and is applicable to a wide audience of potential consumers, regardless of their initial brain function status.
More on Aussie Journal
- This Ain't Press. This Is Pressure — Star Command by RansomXX is Out Now
- An Exclusive VIP Reception Honoring Vocal Prodigy Alliana Lili Yang's Remarkable Achievements and Magazine Cover Spotlight
- Joyce Carol Oates Returns to Hard Case Crime With DOUBLE TROUBLE
- New AI Academy Helps Therapists Embrace Tech Without Losing Their Humanity
- IQSTEL Surges Toward $400M Run Rate with $101.5M in Revenue—Reinforces Billion-Dollar Vision Backed by Fintech, AI, and Cybersecurity
The actual medical study is available as a free open-access publication at https://www.auctoresonline.org/article/effects-of-a-jellyfish-collagen-based-amino-acid-supplement-on-cognitive-function-and-memory-a-pilot-investigation
For further information about the product or study, please contact:
Sara Alkayali at (951) 600-3899 or email: salkayali@certifiednutra.com
Source: Certified Nutraceuticals, Inc.
0 Comments
Latest on Aussie Journal
- Luxurious Estate in Keenes Pointe Hits the Market at $2.9 Million
- CredHub and ManageAmerica Partner to Empower Residents Through Seamless Rent Reporting Integration
- Winter Storms Trigger Rise in Water Damage Across Melbourne: Victoria Hygiene Urges Early Action
- TKSoftware Inc. Unveils ICONIC Pro: The All‑In‑One Medical Billing & Clearinghouse Solution
- Barista Masterclass Sets the Standard for Professional Coffee Training in Melbourne
- MultiTorque Expands Brisbane Operations to Power Australia's Pump Industry
- Baker Rights and Coercive Psychiatry: The Citizens Commission on Human Rights of Florida Hosts Monthly Mental Health Law and Human Rights Seminars
- Venardi Zurada LLP Offers Legal Support to Families After Deadly Lake Tahoe Boat Capsizing
- Elevated Healing Treatment Centers: Redefining Mental Health Care with Compassionate, Evidence-Based, and Accessible Services
- Carlonoscopen Launches Base-Zero Number System — A New Mathematical Language for Tomorrow's Tech
- New Study Reveals Nearly Half Of TikTok Shop Stores Generate Zero Sales Despite Platform's $100 Million Black Friday Success
- Speranza Dental Implant Centers Opens Their First Location
- WWSG Announces Exclusive Speaking Partnership with Former Australian Prime Minister Tony Abbott
- Aidaptive and BizCor Expand Inhabit Partnership with Native Enterprise-Grade Search for Streamline Customers
- Pikmykid Partners with Vivi to Enhance School Emergency Communication and Safety
- AI Meets Cybersecurity: IQSTEL and Cycurion Take Aim at $500 Billion Market Opportunity
- N A S D A Q Compliance Achieved Following Active Trading and Financing, UAE Acquisition & Major Brand Events: Lottery.com Inc., (N A S D A Q: LTRY)
- New Frontier Aerospace Successfully Tests Its Revolutionary Mjölnir Rocket Engine
- Profiting from Elder Harm: The Push to End Psychiatric Drugging in Nursing Homes
- LET Mining launches zero-cost cloud mining, daily rewards + referral double benefits